Compare CHRS & FJDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHRS | FJDI |
|---|---|---|
| Founded | 2010 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 149.4M |
| IPO Year | 2014 | 2025 |
| Metric | CHRS | FJDI |
|---|---|---|
| Price | $1.01 | $9.88 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 73.1K |
| Earning Date | 11-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.19 | N/A |
| Revenue Next Year | $65.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $9.84 |
| 52 Week High | $2.62 | $9.88 |
| Indicator | CHRS | FJDI |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 65.00 |
| Support Level | $0.97 | $9.85 |
| Resistance Level | $1.53 | N/A |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 16.02 | 80.00 |
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
ARC Group Securities Acquisition I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.